26.06.2025

Cerebrolysin® as an Adjunct Therapy to Mechanical Thrombectomy

Stroke remains one of the leading causes of death and long-term disability worldwide, with ischemic stroke accounting for almost 85% of all cases. Mechanical thrombectomy (MT) has revolutionized acute stroke care by restoring blood flow in cases of large vessel occlusions. However, despite timely intervention, many patients still experience significant residual deficits, highlighting the urgent need for complementary therapies that can provide effective cerebroprotection and – as a consequence - functional recovery. A recent study led by Dr. Jacek Staszewski and colleagues, published in Translational Stroke Research presents evidence that Cerebrolysin®, when used as an adjunct therapy to MT, may significantly improve outcomes for patients suffering from AIS due to large vessel occlusion.

The study demonstrated a significant improvement in functional independence at day 90  (mRS 0-2)  in the Cerebrolysin® group compared to the control arm (68% vs. 44%).

Distribution of 7-, 30-, and 90-day modified Rankin scale scores for patients treated with EVT and Cerebrolysin® vs historical controls

This study suggests that Cerebrolysin® could play a valuable role in improving recovery in AIS patients treated with recanalization therapy.

Cerebrolysin® enhances safety and efficacy of recanalization treatment

  • Significant improvement of functional independence
  • Reduction of hemorrhagic complications
  • Early recovery
  • Reduced therapeutic costs
  • Regained independence
More News